Trial Profile
A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Irinotecan (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 19 Apr 2017 New trial record